Legend Biotech. Every tracked FinTwit mention of $LEGN, newest first. 23 mentions since the first on Jun 6, 2025. See the price chart.
June 2026 · 3 mentions
Jun 2
Jacob Plieth — Umer @ Evercore: DL2 data great, but need to understand why zero responses in DL1. Also unclear what the actual LB2501 doses were $LEGN #EHA2026↗
Jun 2
Jacob Plieth — $LEGN in vivo CD19 x CD20 Car-T LB2501: 0% ORR at dose level 1, 100% ORR (6/6), 83% CR rate (5/6) at dose level 2 #EHA2026 https://t.co/AjbY4Ja75a↗
Jun 2
Jacob Plieth — #ASCO26 not over yet, and here come the #EHA2026 late-breakers $LEGN https://t.co/GCiBaUe5m6↗
Jacob Plieth — $GILD buys $ACLX before approval. Via @ApexOnco -> https://t.co/pKF78Wyrww $LEGN $JNJ↗
Feb 12
Jacob Plieth — $LEGN quietly making a big push into in vivo Car-T:
LVIVO-TaVec100 (CD19 x CD20)
LVIVO-TaVec200 (GPRC5D)
LVIVO-TaVec400 (target undisclosed)
...all recently entered human trials.↗
December 2025 · 2 mentions
Dec 9
Jacob Plieth — $JNJ Tecvayli (& $LEGN Carvykti) "entering a new era of resetting survival expectations in a cancer historically described as incurable". @ByMadeleineA @ApexOnco from #ASH25 on…↗
Dec 7
Adam Feuerstein ✡️ — New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment https://t.co/h2TMrtrufE $GILD $ACLX $JNJ $LEGN #ASH25↗
November 2025 · 1 mention
Nov 3
Jacob Plieth — $CRBU +175% premarket, opened +30%, now flat. My take on the latest Antler data, via @ApexOnco -> https://t.co/GNYYkqjUsm $ALLO $GILD $ACLX $LEGN↗
Jacob Plieth — Interesting take on the FcRH5 landscape, which seems to be one of $RHHBY's main oncology R&D areas of interest. $MRNA & $LEGN active here https://t.co/87JPjuwyu5↗
Sep 10
Jacob Plieth — In 2023 $NVS paid $LEGN $100m for an anti-DLL3 Car-T. First human data at #WCLC25 show that this still a work in progress. Via @ApexOnco -> https://t.co/sXZa93t77h↗
August 2025 · 1 mention
Aug 21
Jacob Plieth — Plus some other #WCLC25 presentations of note: https://t.co/xavXaIItJu $LEGN $TIL $NVS $BNTX $CADL↗
July 2025 · 3 mentions
Jul 18
Jacob Plieth — Fascinating Evercore ISI webinar going on right now about disconnect between value of Sino deal and what $MRK owes Lanova on the PD-1 x VEGF.
In summary: 40% of $588m MRK up front…↗
Jul 17
Jacob Plieth — ...and more, this time from the FDA's Andrea Baines $BMY $JNJ $GSK $LEGN https://t.co/8UEG4QyKPq↗
Jacob Plieth — Heads up: a Claudin18.2 Car-T has just been filed for approval*. Via @ApexOnco -> https://t.co/uXpt2keT2W $ALMPF $LEGN $AZN
*in China.↗
Jun 13
Jacob Plieth — @Nicole_Paulk @iskander $LEGN & Starna now in clinical trials with in vivo Car-T https://t.co/0zn7Q65hLK↗
Jun 6
Jacob Plieth — 2 new in vivo Car-T projects just started phase 1:
$LEGN LVIVO-TaVec100 -> https://t.co/iWmPbOlcw7
Starna STR-P004 -> https://t.co/FBIj0K4EhR↗